Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Standard of care

Itacitinib may be taken without regard to food.

"* Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~* Screening, day 14, day 28, day 42, day 74, day 100, day 180, taper period, and follow-up period (expansion study)"

"* Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~* Screening, day 14, day 28, day 42, day 60, day 74, day 100, day 180, taper period, and follow-up period (expansion study)"